|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
ALOX (especially ALOX15) may be involved in the sensitivity of cancer cells to treatment.
|
31314163 |
2019 |
|
Primary malignant neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Inherited polymorphisms in 12-LOX and COX-2 contributed to differential expression or activity of these enzymes might confer interindividual susceptibility to cancer.
|
17460548 |
2007 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Although several studies have shown that 15-LOX-1 has an antitumorigenic role in many different cancer models, including breast cancer, the role of the protein in cancer drug resistance has not been established yet.
|
31663148 |
2020 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We found that (i) the adenoviral vector 5/3 fiber modification enhanced 15-LOX-1 gene transduction in various colorectal cancer cell lines, (ii) the adenoviral vector delivery restored 15-LOX-1 expression and enzymatic activity to therapeutic levels in colon cancer cell lines, and (iii) 15-LOX-1 expression downregulated the expression of the antiapoptotic proteins X-linked inhibitor of apoptosis protein (XIAP) and BcL-XL, activated caspase-3, triggered apoptosis, and inhibited cancer cell survival in vitro and the growth of colon cancer xenografts in vivo.
|
18388920 |
2008 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of Alox15 altered expression of PTEN, PI3K/AKT, and the transcription factor ICSBP, which are known mediators of cancer pathogenesis.
|
25105362 |
2014 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Aim of this article is to describe the role and regulation of 15-LOX-1 in colorectal cancer and highlight its importance in cancer therapeutics.
|
19752603 |
2009 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the exact mechanism underlying 15-LOX-1 transcriptional reactivation in cancer cells is still undefined, especially in regard to the contribution of 15-LOX-1 promoter histone modifications.
|
18799463 |
2008 |
|
Primary malignant neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of 15-lipoxygenase-1 (15-LOX-1) enzyme and high activity of its metabolic pathway is reported to be a driver for prostate cancer malignancy.
|
29940744 |
2018 |
|
Diabetes Mellitus
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Isolated constituents were evaluated <i>in silico</i> and <i>in vitro</i> in assays related to the traditional use against diabetes (inhibition of α-glucosidase activity; inhibition of advanced glycation endproducts) and in inflammatory conditions (inhibition of AAPH induced linoleic acid peroxidation, inhibition of 15-LOX, antimicrobial activity).
|
28507520 |
2017 |
|
Diabetes Mellitus
|
0.090 |
Biomarker
|
group |
BEFREE |
Analysis of plasma bioactive lipids' heat map revealed that the activity of circulating 12/15-LO was not altered by diabetes as evident by no significant changes in the plasma levels of major metabolites derived from 12/15-lipoxygenation of different PUFAs, including linoleic acid (13-HODE), arachidonic acid (12- and 15- HETEs), eicosapentaenoic acid (12- and 15- HEPEs), or docosahexaenoic acid (17-HDoHE).
|
28351645 |
2017 |
|
Diabetes Mellitus
|
0.090 |
Biomarker
|
group |
BEFREE |
Furthermore, splenocytes from NOD-Alox15(null) mice are unable to transfer diabetes in an adoptive transfer model.
|
23437231 |
2013 |
|
Diabetes Mellitus
|
0.090 |
Biomarker
|
group |
BEFREE |
Here, we describe the function and role of human 12-LOX, and mouse 12-LOX and 12/15-LOX, in the development of diabetes and diabetes-related complications, and describe promise in the development of strategies to limit pro-inflammatory metabolites, primarily via new small molecule 12-LOX inhibitors.
|
30347209 |
2019 |
|
Diabetes Mellitus
|
0.090 |
AlteredExpression
|
group |
BEFREE |
Increased expression and activity of 12/15-lipoxygenase (12/15-LO) in vascular smooth muscle cells (VSMCs) play a key role in the pathogenesis of diabetes and vascular complications.
|
17943024 |
2008 |
|
Diabetes Mellitus
|
0.090 |
Biomarker
|
group |
BEFREE |
For in vivo studies, experimental diabetes was induced in wild-type (WT) mice and 12/15-Lo (also known as Alox15) knockout mice (12/15-Lo<sup>-/-</sup>); ER stress was then evaluated after 12-14 weeks of diabetes.
|
29468369 |
2018 |
|
Diabetes Mellitus
|
0.090 |
Biomarker
|
group |
BEFREE |
Examination of knockout and transgenic animals revealed important roles for 12/15-LOX in inflammatory diseases, including atherosclerosis, cancer, osteoporosis, angiotension II-dependent hypertension and diabetes.
|
16678271 |
2006 |
|
Diabetes Mellitus
|
0.090 |
Biomarker
|
group |
BEFREE |
The leukocyte-type 12/15-lipoxygenase (12/15-LO) has been implicated in the pathogenesis of atherosclerosis, hypertension, and diabetes.
|
15576842 |
2005 |
|
Diabetes Mellitus
|
0.090 |
Biomarker
|
group |
BEFREE |
In addition, baicalein can protect rat cortical neurons from damage caused by diabetes via inhibiting the 12/15-LOX pathway and relieving inflammation and apoptosis of the central nervous system.
|
30659940 |
2019 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
These findings have important implications for the use of 12/15-LOX inhibitors in the treatment of stroke.
|
31562627 |
2019 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
12/15-Lipoxygenase (12/15-LOX) contributes to the brain damage after middle cerebral artery occlusion (MCAO) in the acute phase of stroke.
|
29079502 |
2018 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
12/15-lipoxygenase (12/15-LOX) is a major contributor to delayed neuronal cell death and vascular injury in experimental stroke, but a possible role in brain injury following global ischemia has to date not been investigated.
|
27838820 |
2017 |
|
Cerebrovascular accident
|
0.040 |
Biomarker
|
group |
BEFREE |
This study was designed to test the hypothesis that 12/15-lipoxygenase (12/15-LOX) inhibition would reduce HT in warfarin-treated mice subjected to experimental stroke.
|
28057806 |
2017 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
A statistically significantly greater number of cases were found to have an elevated level of 12-LOX among T3, high grade, and surgical margin-positive than T2, intermediate, and low grade, and surgical margin-negative prostatic adenocarcinomas.
|
7624992 |
1995 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
LHGDN |
Concordant induction of 15-lipoxygenase-1 and mutant p53 expression in human prostate adenocarcinoma: correlation with Gleason staging.
|
11023533 |
2000 |
|
Adenocarcinoma
|
0.030 |
AlteredExpression
|
group |
LHGDN |
15-lipoxygenase-1 overexpression in prostate adenocarcinoma.
|
12664577 |
2002 |
|
Carcinoma
|
0.030 |
AlteredExpression
|
group |
BEFREE |
Down-regulation of 15-LOX-1 is an early event in the adenoma to carcinoma sequence, and reversal with celecoxib may represent one mechanism for chemoprevention of polyps or treatment of carcinomas.
|
15912043 |
2005 |